Global Diabetic Retinopathy Drugs Market Growth 2025-2031

October 2025 | 100 pages | ID: GA425180A54DEN
LP Information

Abstracts

The global Diabetic Retinopathy Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Diabetic Retinopathy Drugs Industry Forecast? looks at past sales and reviews total world Diabetic Retinopathy Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Diabetic Retinopathy Drugs sales for 2025 through 2031. With Diabetic Retinopathy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Retinopathy Drugs industry.

This Insight Report provides a comprehensive analysis of the global Diabetic Retinopathy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Retinopathy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Diabetic Retinopathy Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Retinopathy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Retinopathy Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Retinopathy Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Lucentis
• Optina
• Iluvien
• Betamethazone
• Ozurdex
• Others

Segmentation by Application:

• 50-60 Years Old
• 60-70 Years Old
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Novartis
• Bayer Healthcare
• Roche
• Neurotech Pharmaceuticals
• Regeneron Pharmaceuticals
• Allergan

Key Questions Addressed in this Report

What is the 10-year outlook for the global Diabetic Retinopathy Drugs market?
What factors are driving Diabetic Retinopathy Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Diabetic Retinopathy Drugs market opportunities vary by end market size?
How does Diabetic Retinopathy Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Diabetic Retinopathy Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Diabetic Retinopathy Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Diabetic Retinopathy Drugs by Country/Region, 2020, 2024 & 2031
2.2 Diabetic Retinopathy Drugs Segment by Type
  2.2.1 Lucentis
  2.2.2 Optina
  2.2.3 Iluvien
  2.2.4 Betamethazone
  2.2.5 Ozurdex
  2.2.6 Others
2.3 Diabetic Retinopathy Drugs Sales by Type
  2.3.1 Global Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Diabetic Retinopathy Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Diabetic Retinopathy Drugs Sale Price by Type (2020-2025)
2.4 Diabetic Retinopathy Drugs Segment by Application
  2.4.1 50-60 Years Old
  2.4.2 60-70 Years Old
  2.4.3 Others
2.5 Diabetic Retinopathy Drugs Sales by Application
  2.5.1 Global Diabetic Retinopathy Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Diabetic Retinopathy Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Diabetic Retinopathy Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Diabetic Retinopathy Drugs Breakdown Data by Company
  3.1.1 Global Diabetic Retinopathy Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Diabetic Retinopathy Drugs Sales Market Share by Company (2020-2025)
3.2 Global Diabetic Retinopathy Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Diabetic Retinopathy Drugs Revenue by Company (2020-2025)
  3.2.2 Global Diabetic Retinopathy Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Diabetic Retinopathy Drugs Sale Price by Company
3.4 Key Manufacturers Diabetic Retinopathy Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Diabetic Retinopathy Drugs Product Location Distribution
  3.4.2 Players Diabetic Retinopathy Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DIABETIC RETINOPATHY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Diabetic Retinopathy Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Diabetic Retinopathy Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Diabetic Retinopathy Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Diabetic Retinopathy Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Diabetic Retinopathy Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Diabetic Retinopathy Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Diabetic Retinopathy Drugs Sales Growth
4.4 APAC Diabetic Retinopathy Drugs Sales Growth
4.5 Europe Diabetic Retinopathy Drugs Sales Growth
4.6 Middle East & Africa Diabetic Retinopathy Drugs Sales Growth

5 AMERICAS

5.1 Americas Diabetic Retinopathy Drugs Sales by Country
  5.1.1 Americas Diabetic Retinopathy Drugs Sales by Country (2020-2025)
  5.1.2 Americas Diabetic Retinopathy Drugs Revenue by Country (2020-2025)
5.2 Americas Diabetic Retinopathy Drugs Sales by Type (2020-2025)
5.3 Americas Diabetic Retinopathy Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Diabetic Retinopathy Drugs Sales by Region
  6.1.1 APAC Diabetic Retinopathy Drugs Sales by Region (2020-2025)
  6.1.2 APAC Diabetic Retinopathy Drugs Revenue by Region (2020-2025)
6.2 APAC Diabetic Retinopathy Drugs Sales by Type (2020-2025)
6.3 APAC Diabetic Retinopathy Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Diabetic Retinopathy Drugs by Country
  7.1.1 Europe Diabetic Retinopathy Drugs Sales by Country (2020-2025)
  7.1.2 Europe Diabetic Retinopathy Drugs Revenue by Country (2020-2025)
7.2 Europe Diabetic Retinopathy Drugs Sales by Type (2020-2025)
7.3 Europe Diabetic Retinopathy Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Diabetic Retinopathy Drugs by Country
  8.1.1 Middle East & Africa Diabetic Retinopathy Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Diabetic Retinopathy Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Diabetic Retinopathy Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Diabetic Retinopathy Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Diabetic Retinopathy Drugs
10.3 Manufacturing Process Analysis of Diabetic Retinopathy Drugs
10.4 Industry Chain Structure of Diabetic Retinopathy Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Diabetic Retinopathy Drugs Distributors
11.3 Diabetic Retinopathy Drugs Customer

12 WORLD FORECAST REVIEW FOR DIABETIC RETINOPATHY DRUGS BY GEOGRAPHIC REGION

12.1 Global Diabetic Retinopathy Drugs Market Size Forecast by Region
  12.1.1 Global Diabetic Retinopathy Drugs Forecast by Region (2026-2031)
  12.1.2 Global Diabetic Retinopathy Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Diabetic Retinopathy Drugs Forecast by Type (2026-2031)
12.7 Global Diabetic Retinopathy Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Novartis
  13.1.1 Novartis Company Information
  13.1.2 Novartis Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.1.3 Novartis Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Novartis Main Business Overview
  13.1.5 Novartis Latest Developments
13.2 Bayer Healthcare
  13.2.1 Bayer Healthcare Company Information
  13.2.2 Bayer Healthcare Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.2.3 Bayer Healthcare Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Bayer Healthcare Main Business Overview
  13.2.5 Bayer Healthcare Latest Developments
13.3 Roche
  13.3.1 Roche Company Information
  13.3.2 Roche Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.3.3 Roche Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Roche Main Business Overview
  13.3.5 Roche Latest Developments
13.4 Neurotech Pharmaceuticals
  13.4.1 Neurotech Pharmaceuticals Company Information
  13.4.2 Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.4.3 Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Neurotech Pharmaceuticals Main Business Overview
  13.4.5 Neurotech Pharmaceuticals Latest Developments
13.5 Regeneron Pharmaceuticals
  13.5.1 Regeneron Pharmaceuticals Company Information
  13.5.2 Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.5.3 Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Regeneron Pharmaceuticals Main Business Overview
  13.5.5 Regeneron Pharmaceuticals Latest Developments
13.6 Allergan
  13.6.1 Allergan Company Information
  13.6.2 Allergan Diabetic Retinopathy Drugs Product Portfolios and Specifications
  13.6.3 Allergan Diabetic Retinopathy Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Allergan Main Business Overview
  13.6.5 Allergan Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Diabetic Retinopathy Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Diabetic Retinopathy Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Lucentis
Table 4. Major Players of Optina
Table 5. Major Players of Iluvien
Table 6. Major Players of Betamethazone
Table 7. Major Players of Ozurdex
Table 8. Major Players of Others
Table 9. Global Diabetic Retinopathy Drugs Sales by Type (2020-2025) & (K MT)
Table 10. Global Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
Table 11. Global Diabetic Retinopathy Drugs Revenue by Type (2020-2025) & ($ million)
Table 12. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2020-2025)
Table 13. Global Diabetic Retinopathy Drugs Sale Price by Type (2020-2025) & (USD/MT)
Table 14. Global Diabetic Retinopathy Drugs Sale by Application (2020-2025) & (K MT)
Table 15. Global Diabetic Retinopathy Drugs Sale Market Share by Application (2020-2025)
Table 16. Global Diabetic Retinopathy Drugs Revenue by Application (2020-2025) & ($ million)
Table 17. Global Diabetic Retinopathy Drugs Revenue Market Share by Application (2020-2025)
Table 18. Global Diabetic Retinopathy Drugs Sale Price by Application (2020-2025) & (USD/MT)
Table 19. Global Diabetic Retinopathy Drugs Sales by Company (2020-2025) & (K MT)
Table 20. Global Diabetic Retinopathy Drugs Sales Market Share by Company (2020-2025)
Table 21. Global Diabetic Retinopathy Drugs Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Diabetic Retinopathy Drugs Revenue Market Share by Company (2020-2025)
Table 23. Global Diabetic Retinopathy Drugs Sale Price by Company (2020-2025) & (USD/MT)
Table 24. Key Manufacturers Diabetic Retinopathy Drugs Producing Area Distribution and Sales Area
Table 25. Players Diabetic Retinopathy Drugs Products Offered
Table 26. Diabetic Retinopathy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Diabetic Retinopathy Drugs Sales by Geographic Region (2020-2025) & (K MT)
Table 30. Global Diabetic Retinopathy Drugs Sales Market Share Geographic Region (2020-2025)
Table 31. Global Diabetic Retinopathy Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Diabetic Retinopathy Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Diabetic Retinopathy Drugs Sales by Country/Region (2020-2025) & (K MT)
Table 34. Global Diabetic Retinopathy Drugs Sales Market Share by Country/Region (2020-2025)
Table 35. Global Diabetic Retinopathy Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Diabetic Retinopathy Drugs Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Diabetic Retinopathy Drugs Sales by Country (2020-2025) & (K MT)
Table 38. Americas Diabetic Retinopathy Drugs Sales Market Share by Country (2020-2025)
Table 39. Americas Diabetic Retinopathy Drugs Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Diabetic Retinopathy Drugs Sales by Type (2020-2025) & (K MT)
Table 41. Americas Diabetic Retinopathy Drugs Sales by Application (2020-2025) & (K MT)
Table 42. APAC Diabetic Retinopathy Drugs Sales by Region (2020-2025) & (K MT)
Table 43. APAC Diabetic Retinopathy Drugs Sales Market Share by Region (2020-2025)
Table 44. APAC Diabetic Retinopathy Drugs Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Diabetic Retinopathy Drugs Sales by Type (2020-2025) & (K MT)
Table 46. APAC Diabetic Retinopathy Drugs Sales by Application (2020-2025) & (K MT)
Table 47. Europe Diabetic Retinopathy Drugs Sales by Country (2020-2025) & (K MT)
Table 48. Europe Diabetic Retinopathy Drugs Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Diabetic Retinopathy Drugs Sales by Type (2020-2025) & (K MT)
Table 50. Europe Diabetic Retinopathy Drugs Sales by Application (2020-2025) & (K MT)
Table 51. Middle East & Africa Diabetic Retinopathy Drugs Sales by Country (2020-2025) & (K MT)
Table 52. Middle East & Africa Diabetic Retinopathy Drugs Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Diabetic Retinopathy Drugs Sales by Type (2020-2025) & (K MT)
Table 54. Middle East & Africa Diabetic Retinopathy Drugs Sales by Application (2020-2025) & (K MT)
Table 55. Key Market Drivers & Growth Opportunities of Diabetic Retinopathy Drugs
Table 56. Key Market Challenges & Risks of Diabetic Retinopathy Drugs
Table 57. Key Industry Trends of Diabetic Retinopathy Drugs
Table 58. Diabetic Retinopathy Drugs Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Diabetic Retinopathy Drugs Distributors List
Table 61. Diabetic Retinopathy Drugs Customer List
Table 62. Global Diabetic Retinopathy Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 63. Global Diabetic Retinopathy Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Diabetic Retinopathy Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 65. Americas Diabetic Retinopathy Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Diabetic Retinopathy Drugs Sales Forecast by Region (2026-2031) & (K MT)
Table 67. APAC Diabetic Retinopathy Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Diabetic Retinopathy Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 69. Europe Diabetic Retinopathy Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Diabetic Retinopathy Drugs Sales Forecast by Country (2026-2031) & (K MT)
Table 71. Middle East & Africa Diabetic Retinopathy Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Diabetic Retinopathy Drugs Sales Forecast by Type (2026-2031) & (K MT)
Table 73. Global Diabetic Retinopathy Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Diabetic Retinopathy Drugs Sales Forecast by Application (2026-2031) & (K MT)
Table 75. Global Diabetic Retinopathy Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. Novartis Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 77. Novartis Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 78. Novartis Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. Bayer Healthcare Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Bayer Healthcare Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 83. Bayer Healthcare Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 84. Bayer Healthcare Main Business
Table 85. Bayer Healthcare Latest Developments
Table 86. Roche Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Roche Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 88. Roche Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 89. Roche Main Business
Table 90. Roche Latest Developments
Table 91. Neurotech Pharmaceuticals Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 93. Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 94. Neurotech Pharmaceuticals Main Business
Table 95. Neurotech Pharmaceuticals Latest Developments
Table 96. Regeneron Pharmaceuticals Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 98. Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 99. Regeneron Pharmaceuticals Main Business
Table 100. Regeneron Pharmaceuticals Latest Developments
Table 101. Allergan Basic Information, Diabetic Retinopathy Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Allergan Diabetic Retinopathy Drugs Product Portfolios and Specifications
Table 103. Allergan Diabetic Retinopathy Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 104. Allergan Main Business
Table 105. Allergan Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Diabetic Retinopathy Drugs
Figure 2. Diabetic Retinopathy Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Diabetic Retinopathy Drugs Sales Growth Rate 2020-2031 (K MT)
Figure 7. Global Diabetic Retinopathy Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Diabetic Retinopathy Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Diabetic Retinopathy Drugs Sales Market Share by Country/Region (2024)
Figure 10. Diabetic Retinopathy Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Lucentis
Figure 12. Product Picture of Optina
Figure 13. Product Picture of Iluvien
Figure 14. Product Picture of Betamethazone
Figure 15. Product Picture of Ozurdex
Figure 16. Product Picture of Others
Figure 17. Global Diabetic Retinopathy Drugs Sales Market Share by Type in 2025
Figure 18. Global Diabetic Retinopathy Drugs Revenue Market Share by Type (2020-2025)
Figure 19. Diabetic Retinopathy Drugs Consumed in 50-60 Years Old
Figure 20. Global Diabetic Retinopathy Drugs Market: 50-60 Years Old (2020-2025) & (K MT)
Figure 21. Diabetic Retinopathy Drugs Consumed in 60-70 Years Old
Figure 22. Global Diabetic Retinopathy Drugs Market: 60-70 Years Old (2020-2025) & (K MT)
Figure 23. Diabetic Retinopathy Drugs Consumed in Others
Figure 24. Global Diabetic Retinopathy Drugs Market: Others (2020-2025) & (K MT)
Figure 25. Global Diabetic Retinopathy Drugs Sale Market Share by Application (2024)
Figure 26. Global Diabetic Retinopathy Drugs Revenue Market Share by Application in 2025
Figure 27. Diabetic Retinopathy Drugs Sales by Company in 2025 (K MT)
Figure 28. Global Diabetic Retinopathy Drugs Sales Market Share by Company in 2025
Figure 29. Diabetic Retinopathy Drugs Revenue by Company in 2025 ($ millions)
Figure 30. Global Diabetic Retinopathy Drugs Revenue Market Share by Company in 2025
Figure 31. Global Diabetic Retinopathy Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Diabetic Retinopathy Drugs Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Diabetic Retinopathy Drugs Sales 2020-2025 (K MT)
Figure 34. Americas Diabetic Retinopathy Drugs Revenue 2020-2025 ($ millions)
Figure 35. APAC Diabetic Retinopathy Drugs Sales 2020-2025 (K MT)
Figure 36. APAC Diabetic Retinopathy Drugs Revenue 2020-2025 ($ millions)
Figure 37. Europe Diabetic Retinopathy Drugs Sales 2020-2025 (K MT)
Figure 38. Europe Diabetic Retinopathy Drugs Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Diabetic Retinopathy Drugs Sales 2020-2025 (K MT)
Figure 40. Middle East & Africa Diabetic Retinopathy Drugs Revenue 2020-2025 ($ millions)
Figure 41. Americas Diabetic Retinopathy Drugs Sales Market Share by Country in 2025
Figure 42. Americas Diabetic Retinopathy Drugs Revenue Market Share by Country (2020-2025)
Figure 43. Americas Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
Figure 44. Americas Diabetic Retinopathy Drugs Sales Market Share by Application (2020-2025)
Figure 45. United States Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Diabetic Retinopathy Drugs Sales Market Share by Region in 2025
Figure 50. APAC Diabetic Retinopathy Drugs Revenue Market Share by Region (2020-2025)
Figure 51. APAC Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
Figure 52. APAC Diabetic Retinopathy Drugs Sales Market Share by Application (2020-2025)
Figure 53. China Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. India Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Diabetic Retinopathy Drugs Sales Market Share by Country in 2025
Figure 61. Europe Diabetic Retinopathy Drugs Revenue Market Share by Country (2020-2025)
Figure 62. Europe Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
Figure 63. Europe Diabetic Retinopathy Drugs Sales Market Share by Application (2020-2025)
Figure 64. Germany Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. France Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Diabetic Retinopathy Drugs Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Diabetic Retinopathy Drugs Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Diabetic Retinopathy Drugs Sales Market Share by Application (2020-2025)
Figure 72. Egypt Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Diabetic Retinopathy Drugs Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Diabetic Retinopathy Drugs in 2025
Figure 78. Manufacturing Process Analysis of Diabetic Retinopathy Drugs
Figure 79. Industry Chain Structure of Diabetic Retinopathy Drugs
Figure 80. Channels of Distribution
Figure 81. Global Diabetic Retinopathy Drugs Sales Market Forecast by Region (2026-2031)
Figure 82. Global Diabetic Retinopathy Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Diabetic Retinopathy Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Diabetic Retinopathy Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Diabetic Retinopathy Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Diabetic Retinopathy Drugs Revenue Market Share Forecast by Application (2026-2031)